Remdesivir-Associated Significant Bradycardia: A Report of Three Cases

Recently, remdesivir was approved by the United States Food and Drug Administration for patients with Coronavirus disease 2019 (COVID-19). We herein describe 3 patients with COVID-19 who showed significant bradycardia and QTc prolongation after remdesivir administration. Bradycardia did not respond...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirvani, Maria, Sayad, Babak, Shojaei, Lida, Amini, Azadeh, Shahbazi, Foroud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences, 2006- 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742862/
https://www.ncbi.nlm.nih.gov/pubmed/35082876
http://dx.doi.org/10.18502/jthc.v16i2.7390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742862/
https://www.ncbi.nlm.nih.gov/pubmed/35082876
http://dx.doi.org/10.18502/jthc.v16i2.7390

Ejemplares similares